CoChat

Incretin-based therapies for the treatment of obesity-related diseases

Open access

The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index; 37 of the 117 sources its claims cite were checked for support.

Abstract

Obesity-related disability-adjusted life years (DALYs) are expected to increase by approximately 40% from 2020 to 2030. DALYs and mortality related to obesity are the consequence of multiple comorbidities such as cardiovascular (i.e., heart failure) and metabolic diseases (i.e. type 2 diabetes [T2D], metabolic dysfunction-associated steatotic liver disease [MASLD]). Lifestyle interventions represent the foundation of obesity treatment, yet an escalation to pharmacological and/or surgical interventions is often needed. Liraglutide, semaglutide and tirzepatide are incretin-based therapies currently approved by FDA for the management of obesity, while triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), the cagrilintide/semaglutide (CagriSema) 2.4 mg combination, high-dose oral semaglutide, and oral orforglipron are in advanced stages of development. Incretin-based therapies have been associated with a body weight (BW) reduction of ≥5% in at least half of patients in most randomized controlled trials (RCT) and real-world studies (RWS). Semaglutide and tirzepatide have also displayed a mean 60-69% 10-years relative risk reduction of T2D development. In line with evidence accrued in patients with T2D, incretin-based therapies produced a favorable effect on traditional cardiovascular risk factors, such as lipids and blood pressure, and even reduced the risk of major cardiovascular events and heart failure-related events in individuals with obesity, as recently demonstrated for the first time in the SELECT trial with semaglutide 2.4 mg once-weekly. Moreover, incretin-based therapies have also been proven beneficial on obesity-related comorbidities, such as knee osteoarthritis (KOA), obstructive sleep apnea (OSA) syndrome, and MASLD. Further research is needed to improve our understanding of their effects on obesity-related comorbidities and the underlying mechanism, whether involving direct effects on target tissues or mediated by improvement in BW, glucose levels and other CV risk factors.

Overview

CoChat Summary

TL;DR

This narrative review summarizes incretin-based therapies for obesity and obesity-related diseases, reporting substantial weight loss and benefits for type 2 diabetes prevention, cardiovascular risk factors, and several comorbidities. It concludes that liraglutide, semaglutide, and tirzepatide are effective, with newer agents such as retatrutide, CagriSema, oral semaglutide, and orforglipron in advanced development.

Key findings

  • Incretin-based therapies were associated with body weight reduction of ≥5% in at least half of patients in most randomized controlled trials and real-world studies; semaglutide and tirzepatide showed a mean 60–69% 10-year relative risk reduction of type 2 diabetes development.
  • In RCTs, liraglutide 3.0 mg produced 6.1–8.0% body weight loss vs. 0.2–4.0% with placebo at 56 weeks; semaglutide 2.4 mg produced 14.8–16.0% vs. 2.4–5.7% at 68 weeks; tirzepatide 15 mg produced 20.9% vs. 3.1% at 72 weeks; retatrutide 12 mg produced up to −24.2% at 48 weeks.
  • The SELECT trial showed once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events (HR 0.80, 95% CI 0.72–0.90, p < 0.001), heart failure composite endpoint (HR 0.82, 95% CI 0.71–0.96), and death from any cause (HR 0.81, 95% CI 0.71–0.93).
  • For comorbidities, SYNERGY-NASH reported biopsy-proven MASH resolution in 62% with tirzepatide 15 mg vs. 10% with placebo; SURMOUNT OSA showed 17.7–19.6% body weight reduction vs. 1.6–2.3% with placebo; SCALE Sleep Apnea showed apnea-hypopnea index reduction of −6.1 events per hour vs. placebo.

Methods

  • Design: narrative review of incretin-based therapies for obesity-related diseases, including liraglutide, semaglutide, tirzepatide, retatrutide, CagriSema, oral semaglutide, orforglipron, and other agents in development.
  • Data: published randomized controlled trials (SCALE, STEP, SURMOUNT, SELECT, OASIS 1, SYNERGY-NASH, SURMOUNT OSA, etc.), real-world studies, and meta-analyses; no primary patient data were collected.
  • Analysis: descriptive synthesis of efficacy, effectiveness, diabetes prevention, cardiovascular risk factors, cardiovascular complications, other obesity-related comorbidities, and treatment adherence, with summary tables and figures.

Limitations

  • Stated: further research is needed to understand effects on obesity-related comorbidities and underlying mechanisms, whether direct on target tissues or mediated by improvements in body weight, glucose levels, and other cardiovascular risk factors.
  • Stated: adherence, prediction of response to treatment, and economic barriers to access remain unresolved and may require complex, multifaceted approaches.
  • Evident: this is a narrative review without a stated systematic search strategy or formal risk-of-bias assessment; many cited trials are ongoing or not yet disclosed (e.g., STEP 10, FLOW, cardiovascular safety trials for tirzepatide and CagriSema), and real-world studies are noted to have small samples, limited adherence/dose information, and approximately 6-month follow-up.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s44324-024-00030-5

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Fig. 1 Proportion of participants with at least 5%, 10%, 15%, 20%, 25% body weight loss across dedicated randomized controlled trials with incretin-based anti-obesity medications. In randomized controlled trials investigating multiple doses of the experimental medications, results obtained with the highest dose were reported. Standard errors are not shown for data retrieved from a single study. Liraglutide 3.0 mg was administered subcutaneously once daily (refs. 11–14,16–18,26); Semaglutide 2.4 mg (refs. 20–24,26–28), Tirzepatide 15 mg (refs. 30–33) and Retatrutide 12 mg (refs. 35) were administered subcutaneously once-weekly; Semaglutide 50 mg (refs. 36) and Orforglipron 45 mg (refs. 37.) were administered orally once daily.
Fig. 1 Proportion of participants with at least 5%, 10%, 15%, 20%, 25% body weight loss across dedicated randomized controlled trials with incretin-based anti-obesity medications. In randomized controlled trials investigating multiple doses of the experimental medications, results obtained with the highest dose were reported. Standard errors are not shown for data retrieved from a single study. Liraglutide 3.0 mg was administered subcutaneously once daily (refs. 11–14,16–18,26); Semaglutide 2.4 mg (refs. 20–24,26–28), Tirzepatide 15 mg (refs. 30–33) and Retatrutide 12 mg (refs. 35) were administered subcutaneously once-weekly; Semaglutide 50 mg (refs. 36) and Orforglipron 45 mg (refs. 37.) were administered orally once daily.CC BY-NC-ND · PubMed Central
Fig. 2 Proportion of participants with normoglycemia, prediabetes and type 2 diabetes at baseline and end of study in dedicated randomized controlled trials with incretin-based anti-obesity medications. EOS data refer only to participants with baseline prediabetes. Baseline data for liraglutide 3.0 mg are from SCALE Obesity and Prediabetes (ref. 13), EOS data are from SCALE Obesity and Prediabetes extension (ref. 14). Data for semaglutide 2.4 mg are a mean of the results from STEP 1, 3, 4 (refs. 21–23). Data for tirzepatide (ref. 30) and retatrutide (ref. 35) refer to pooled doses. Liraglutide 3.0 mg was administered subcutaneously once daily; Semaglutide 2.4 mg, Tirzepatide 15 mg and Retatrutide 12 mg were administered subcutaneously once-weekly; Semaglutide 50 mg was administered orally once daily. EOS end of study, Lira liraglutide, Sema semaglutide, T2D type 2 diabetes.
Fig. 2 Proportion of participants with normoglycemia, prediabetes and type 2 diabetes at baseline and end of study in dedicated randomized controlled trials with incretin-based anti-obesity medications. EOS data refer only to participants with baseline prediabetes. Baseline data for liraglutide 3.0 mg are from SCALE Obesity and Prediabetes (ref. 13), EOS data are from SCALE Obesity and Prediabetes extension (ref. 14). Data for semaglutide 2.4 mg are a mean of the results from STEP 1, 3, 4 (refs. 21–23). Data for tirzepatide (ref. 30) and retatrutide (ref. 35) refer to pooled doses. Liraglutide 3.0 mg was administered subcutaneously once daily; Semaglutide 2.4 mg, Tirzepatide 15 mg and Retatrutide 12 mg were administered subcutaneously once-weekly; Semaglutide 50 mg was administered orally once daily. EOS end of study, Lira liraglutide, Sema semaglutide, T2D type 2 diabetes.CC BY-NC-ND · PubMed Central
Fig. 3 Effect of incretin-based anti-obesity medications on lipid profile and blood pressure in dedicated randomized controlled trials. a, b Depict the effect of incretin-based anti-obesity medications on lipid profile and blood pressure, respectively. Liraglutide 3.0 mg was administered subcutaneously once daily (refs. 11–14,16–18,26); Semaglutide 2.4 mg (refs. 20–24,26–28), Tirzepatide (refs. 30–33,38) and Retatrutide were administered subcutaneously once-weekly (ref. 35); Semaglutide 50 mg (ref. 36) and Orforglipron (ref. 37) were administered orally once daily. Data on the effect of Tirzepatide, Retatrutide and Orforglipron were reported for pooled doses. C cholesterol, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lira liraglutide, SBP systolic blood pressure, Sema semaglutide, TG triglycerides, TZP tirzepatide.
Fig. 3 Effect of incretin-based anti-obesity medications on lipid profile and blood pressure in dedicated randomized controlled trials. a, b Depict the effect of incretin-based anti-obesity medications on lipid profile and blood pressure, respectively. Liraglutide 3.0 mg was administered subcutaneously once daily (refs. 11–14,16–18,26); Semaglutide 2.4 mg (refs. 20–24,26–28), Tirzepatide (refs. 30–33,38) and Retatrutide were administered subcutaneously once-weekly (ref. 35); Semaglutide 50 mg (ref. 36) and Orforglipron (ref. 37) were administered orally once daily. Data on the effect of Tirzepatide, Retatrutide and Orforglipron were reported for pooled doses. C cholesterol, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lira liraglutide, SBP systolic blood pressure, Sema semaglutide, TG triglycerides, TZP tirzepatide.CC BY-NC-ND · PubMed Central
Fig. 4 Association of mean between-arm HbA1c difference and the risk of MACE and its components across CVOT trials with GLP-1 receptor agonists. The association of mean between-arm HbA1c difference and MACE HR (a) (R2 = 0.47, p < 0.05) is largely driven by reduction of stroke (b) (R2 = 0.57, p < 0.05) rather than CV mortality (c) or MI (d) HR. CV cardiovascular, HR hazard ratio, MACE major adverse cardiovascular events, MI myocardial infarction.
Fig. 4 Association of mean between-arm HbA1c difference and the risk of MACE and its components across CVOT trials with GLP-1 receptor agonists. The association of mean between-arm HbA1c difference and MACE HR (a) (R2 = 0.47, p < 0.05) is largely driven by reduction of stroke (b) (R2 = 0.57, p < 0.05) rather than CV mortality (c) or MI (d) HR. CV cardiovascular, HR hazard ratio, MACE major adverse cardiovascular events, MI myocardial infarction.CC BY-NC-ND · PubMed Central
Fig. 5 Effect of incretin-based therapies on obesity-related comorbidities. Summary of the effects of incretin-based therapies on obesity-related comorbidities and their underlying mechanisms according to results of studies conducted in individuals with obesity regardless of the presence of diabetes. AE adverse event, AHI apnea-hypopnea index, BW body weight, CKD chronic kidney disease, CV cardiovascular, DBP diastolic blood pressure, ED erectile dysfunction, eGFR estimated glomerular filtration rate, GERD gastroesophageal reflux disease, HF heart failure, hHF hospitalization for heart failure, KCCQ Kansas City Cardiomyopathy Questionnaire, KOA knee osteoarthritis, LDL-c LDL cholesterol, MACE major adverse cardiovascular events, MASH metabolic dysfunction-associated steatohepatitis, MASLD metabolic dysfunction-associated steatotic liver disease, OSA obstructive sleep apnea, PCOS polycystic ovary syndrome, SBP systolic blood pressure, T2D type 2 diabetes, VAT visceral adipose tissue. Underlining identifies results from preclinical studies. Red circles, results applicable to most incretin-based therapies; blue circles, results applicable to liraglutide; green circles, results applicable to semaglutide; purple circles, results applicable to dulaglutide; yellow circles, results applicable to tirzepatide; filled circles indicate mostly BW loss-mediated benefits.
Fig. 5 Effect of incretin-based therapies on obesity-related comorbidities. Summary of the effects of incretin-based therapies on obesity-related comorbidities and their underlying mechanisms according to results of studies conducted in individuals with obesity regardless of the presence of diabetes. AE adverse event, AHI apnea-hypopnea index, BW body weight, CKD chronic kidney disease, CV cardiovascular, DBP diastolic blood pressure, ED erectile dysfunction, eGFR estimated glomerular filtration rate, GERD gastroesophageal reflux disease, HF heart failure, hHF hospitalization for heart failure, KCCQ Kansas City Cardiomyopathy Questionnaire, KOA knee osteoarthritis, LDL-c LDL cholesterol, MACE major adverse cardiovascular events, MASH metabolic dysfunction-associated steatohepatitis, MASLD metabolic dysfunction-associated steatotic liver disease, OSA obstructive sleep apnea, PCOS polycystic ovary syndrome, SBP systolic blood pressure, T2D type 2 diabetes, VAT visceral adipose tissue. Underlining identifies results from preclinical studies. Red circles, results applicable to most incretin-based therapies; blue circles, results applicable to liraglutide; green circles, results applicable to semaglutide; purple circles, results applicable to dulaglutide; yellow circles, results applicable to tirzepatide; filled circles indicate mostly BW loss-mediated benefits.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

20 Valid · 3 Not valid · 64 Not checked · 22 Own results and interpretations

72 more claims · 8 with their cited sources checked

Create a free account to see all 109 claims and to verify the 80 references still open.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 2
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 113 references

Cited by

See all 57

Metadata

Authors
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F.
Affiliations
University of Bari Aldo Moro (IT)
Corresponding author
Giorgino, Francesco
Venue
npj Metabolic Health and Disease
Published
2024-11-06
Volume
2
Issue
1
Pages
31-31
ISSN
2948-2828 (ISSN-L)
OpenAlex
W4404110396
Cited by
48
References
113
Citations by year
2026: 33 · 2025: 15
FWCI
3.01
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Metabolic Health and Disease (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by-nc-nd)
Funders
  • European Commission (DM 155711.10.2022, 11-10-2022)
  • Fondazione per la Ricerca Biomedica
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
incretin-based therapy, obesity, semaglutide, tirzepatide, liraglutide, retatrutide, orforglipron, type 2 diabetes prevention, non-alcoholic fatty liver disease, heart failure, cardiovascular risk, knee osteoarthritis, obstructive sleep apnea, weight loss, GLP-1 receptor agonists, GIP receptor agonist, GIP/GLP-1 receptor agonist

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incretin-based therapies for the treatment of obesity-related diseases. https://app.cochat.ai/papers/10.1038/s44324-024-00030-5
The paper
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024). Incretin-based therapies for the treatment of obesity-related diseases. npj Metabolic Health and Disease. https://doi.org/10.1038/s44324-024-00030-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.